USP to set up new pharma continuous manufacturing facility in Hyderabad
The proposed budget for this new lab is $200K
United States Pharmacopeia (USP) India is setting up a new continuous manufacturing (flow chemistry) facility in Hyderabad – an advanced concept that would enable the manufacturers to gain efficiencies and flexibility in manufacturing processes. The proposed budget for this new lab is $200K.
The announcement was made during Minister KT Rama Rao’s visit to the US in the presence of Stan Burhans, Chief Finance Officer, USP-US and Head of USP India Operations, and Dr KV Surendra Nath, Sr VP, Regions, Strategy and Operations, USP-US. Jayesh Ranjan, Principal Secretary, Industries and Commerce Department and Shakthi M Nagappan, Director Lifesciences, Government of Telangana were also present during the meeting.
USP is an independent, scientific non-profit organisation that sets quality standards for medicines, dietary supplements, and food ingredients, and the state government. In the last two years, USP India has invested $5 million in the development of infrastructure and capital equipment for scientific laboratory and IT.
As per the announcement, the new advanced laboratory with a team of 35 experienced scientists in Hyderabad would support the development of guidelines for new processes/technologies to address some of the challenges in implementing the continuous manufacturing processes. A 12,500 sq foot facility in IKP Knowledge Park is equipped with advanced synthetic and analytical capabilities.
Minister KT Rama Rao said, “I’m delighted to announce USP India’s expansion and a new continuous manufacturing facility in Hyderabad – an advanced concept that would enable the manufacturers to develop their products through continuous manufacturing. The continued expansion and a new investment of this nature in Hyderabad reinforces the city’s leadership position in life sciences sector.”
“This continued investment in the facility in Hyderabad allows us to reinforce our conviction in life science, support pharma industry and promote public health. We anticipate that India and Hyderabad will further cement its position in the global life science arena in the post pandemic world”, said USP in a statement.